Cargando…

Potential for cost economies in guiding therapy in patients with metastatic breast cancer.

Therapeutic response in patients with advanced breast cancer is conventionally assessed with reference to criteria devised by the International Union Against Cancer. Evidence to date suggests, however, that assessments of equivalent quality may be obtained at lower cost from the use of serum markers...

Descripción completa

Detalles Bibliográficos
Autores principales: Robertson, J. F., Whynes, D. K., Dixon, A., Blamey, R. W.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034118/
https://www.ncbi.nlm.nih.gov/pubmed/7599049
_version_ 1782136986572685312
author Robertson, J. F.
Whynes, D. K.
Dixon, A.
Blamey, R. W.
author_facet Robertson, J. F.
Whynes, D. K.
Dixon, A.
Blamey, R. W.
author_sort Robertson, J. F.
collection PubMed
description Therapeutic response in patients with advanced breast cancer is conventionally assessed with reference to criteria devised by the International Union Against Cancer. Evidence to date suggests, however, that assessments of equivalent quality may be obtained at lower cost from the use of serum markers. The paper presents estimates of potential cost savings resulting from the use of serum markers in place of conventional assessment and argues that the size of these savings merits the establishment of a randomised controlled trial.
format Text
id pubmed-2034118
institution National Center for Biotechnology Information
language English
publishDate 1995
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20341182009-09-10 Potential for cost economies in guiding therapy in patients with metastatic breast cancer. Robertson, J. F. Whynes, D. K. Dixon, A. Blamey, R. W. Br J Cancer Research Article Therapeutic response in patients with advanced breast cancer is conventionally assessed with reference to criteria devised by the International Union Against Cancer. Evidence to date suggests, however, that assessments of equivalent quality may be obtained at lower cost from the use of serum markers. The paper presents estimates of potential cost savings resulting from the use of serum markers in place of conventional assessment and argues that the size of these savings merits the establishment of a randomised controlled trial. Nature Publishing Group 1995-07 /pmc/articles/PMC2034118/ /pubmed/7599049 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Robertson, J. F.
Whynes, D. K.
Dixon, A.
Blamey, R. W.
Potential for cost economies in guiding therapy in patients with metastatic breast cancer.
title Potential for cost economies in guiding therapy in patients with metastatic breast cancer.
title_full Potential for cost economies in guiding therapy in patients with metastatic breast cancer.
title_fullStr Potential for cost economies in guiding therapy in patients with metastatic breast cancer.
title_full_unstemmed Potential for cost economies in guiding therapy in patients with metastatic breast cancer.
title_short Potential for cost economies in guiding therapy in patients with metastatic breast cancer.
title_sort potential for cost economies in guiding therapy in patients with metastatic breast cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034118/
https://www.ncbi.nlm.nih.gov/pubmed/7599049
work_keys_str_mv AT robertsonjf potentialforcosteconomiesinguidingtherapyinpatientswithmetastaticbreastcancer
AT whynesdk potentialforcosteconomiesinguidingtherapyinpatientswithmetastaticbreastcancer
AT dixona potentialforcosteconomiesinguidingtherapyinpatientswithmetastaticbreastcancer
AT blameyrw potentialforcosteconomiesinguidingtherapyinpatientswithmetastaticbreastcancer